Advertisement

Diabetologia

, Volume 59, Issue 6, pp 1247–1257 | Cite as

Elevated circulating stearic acid leads to a major lipotoxic effect on mouse pancreatic beta cells in hyperlipidaemia via a miR-34a-5p-mediated PERK/p53-dependent pathway

  • Huimin Lu
  • Liuyi Hao
  • Songtao Li
  • Song Lin
  • Lin Lv
  • Yang Chen
  • Hongli Cui
  • Tianqi Zi
  • Xia Chu
  • Lixin NaEmail author
  • Changhao SunEmail author
Article

Abstract

Aims/hypothesis

Serum stearic acid (C18:0) is elevated in individuals with hyperlipidaemia and type 2 diabetes. However, the lipotoxicity induced by increased stearic acid in beta cells has not been well described. This study aimed to examine the adverse effects of stearic acid on beta cells and the potential mechanisms through which these are mediated.

Methods

Three groups of C57BL/6 mice were fed a normal diet or a high-stearic-acid/high-palmitic-acid diet for 24 weeks, respectively. The microRNA (miR) profiles of islets were determined by microarray screening. Islet injury was detected with co-staining using the TUNEL assay and insulin labelling. A lentiviral vector expressing anti-miRNA-34a-5p oligonucleotide (AMO-34a-5p) was injected into mice via an intraductal pancreatic route.

Results

In both mouse islets and cultured rat insulinoma INS-1 cells, stearic acid exhibited a stronger lipotoxic role than other fatty acids, owing to repression of B cell CLL/lymphoma 2 (BCL-2) and BCL-2-like 2 (BCL-W) by stearic acid stimulation of miR-34a-5p. The stearic-acid-induced lipotoxicity and reduction in insulin secretion were alleviated by AMO-34a-5p. Further investigations in INS-1 cells revealed that p53 was involved in stearic-acid-induced elevation of miR-34a-5p, owing in part to activation of protein kinase-like endoplasmic reticulum kinase (PERK). Conversely, silencing PERK alleviated stearic-acid-induced p53, miR-34a-5p and lipotoxicity.

Conclusions/interpretation

These findings provide new insight for understanding the molecular mechanisms underlying not only the deleterious impact of stearic-acid-induced lipotoxicity but also apoptosis in beta cells and progression to type 2 diabetes.

Keywords

Lipotoxicity MicroRNA Pancreatic beta cells Stearic acid 

Abbreviations

AMO-34a-5p

Anti-miRNA-34a-5p oligonucleotide

ATF6

Activating transcription factor 6

BCL-2

B cell CLL/lymphoma 2

BCL-W

BCL2-like 2

CHOP

CCAAT/enhancer binding protein homologous protein

ER

Endoplasmic reticulum

GSIS

Glucose-induced insulin secretion

HPD

High-palmitic-acid diet

HSD

High-stearic-acid diet

IRE1

Inositol-requiring-enzyme 1

Lenti-AMO-34a-5p

Lentiviral vector expressing anti-miRNA-34a-5p oligonucleotide

miRNA/miR

MicroRNA

MTT

3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide

PERK

Protein kinase-like endoplasmic reticulum kinase

qPCR

Quantitative PCR

SFA

Saturated fatty acids

Introduction

Lipotoxicity refers to the cellular dysfunction caused by an elevated level of NEFA. Accumulating evidence indicates that lipotoxicity contributes to beta cell injury and plays a critical role in the development of type 2 diabetes [1, 2, 3]. NEFA is chemically classified into saturated and unsaturated fatty acids. It is widely accepted that lipotoxicity is mostly induced by long-chain saturated fatty acids (SFA), such as palmitic (C16:0) and stearic acid (C18:0), whereas unsaturated fatty acids are, in general, less toxic, and may even be protective [4, 5, 6].

There is growing evidence that chronic consumption of a diet rich in saturated fats increases circulating SFA levels and the risk of type 2 diabetes [7, 8]. It has been observed that NEFA profiles in individuals with obesity or hyperlipidaemia are substantially altered compared with healthy individuals; such changes are regarded as an important risk factor for type 2 diabetes [7, 9]. Palmitic acid is widely employed as a representative fatty acid to investigate the relationship between SFA and type 2 diabetes because it accounts for the highest percentage of dietary NEFA for the human body. However, whether other alterations in NEFA profiles have a detrimental role in beta cell destruction and type 2 diabetes is unknown. Our previous study revealed that the profiles of both fasting and postprandial serum NEFA were significantly altered in patients with hyperlipidaemia [7]. Most strikingly, we observed that only the proportion of stearic acid in the serum increased dramatically in the postprandial state, which implies that patients with hyperlipidaemia have a considerably higher level of serum stearic acid most of the time. In animal models of insulin resistance, the ratio between palmitic and stearic acids was decreased from 3:1 in the normal group to 2:1 in mice fed a high-fat diet [7]. Research in vitro has clearly shown that increasing stearic acid stimulates severe lipotoxicity in hepatocytes and skeletal muscle cells [5, 10, 11]. Added to our previous observation that an increased proportion of stearic acid in the serum is closely related to insulin resistance [7], we proposed that raising the proportion of stearic acid in the blood makes the greatest contribution to beta cell lipotoxicity relative to other NEFA, and plays a dominant role in type 2 diabetes progression. Moreover, we sought to explore the molecular mechanisms underlying the destructive effect of stearic acid on beta cells.

Although the molecular mechanisms of stearic-acid-induced lipotoxicity are not fully understood, it is evident that enhanced endoplasmic reticulum (ER) stress is a central contributor to lipotoxicity resulting from transcriptional reprogramming [12], activation of c-Jun N-terminal kinase [13], CCAAT/enhancer binding protein homologous protein (CHOP) [14], p53 and mitochondrial apoptosis pathways [15, 16]. Importantly, microRNAs (miRNAs), which are involved in post-transcriptional regulation under ER stress, have emerged as key regulators of hepatocyte and cardiac muscle lipotoxicity [17, 18]. In islet beta cells, the involvement of miRNA in stearic-acid-mediated lipotoxicity is still unclear.

In this study, we hypothesised that increasing stearic acid induces more severe beta cell lipotoxicity than other NEFA and its underlying mechanism is related to miRNA (miR)-34a-5p.

Methods

Materials

Stock solutions of stearic and palmitic acids (Sigma, St Louis, MO, USA) were prepared as described previously [19]. The oligonucleotides and lentivirus are described in the electronic supplementary material (ESM) Methods.

Animal experiments

All experimental procedures followed guidelines for the care and use of animals established by Harbin Medical University and approved by the Animal Experimentation Ethics Committee of Harbin Medical University. Seven-week-old male C57BL/6 mice were purchased from Vital River Laboratories (Beijing, China) and completely randomised to receive a normal diet, a high-stearic-acid diet (HSD) or a high-palmitic-acid diet (HPD) (ESM Table 1). A lentiviral vector expressing anti-miRNA-34a-5p oligonucleotide (AMO-34a-5p) (lenti-AMO-34a-5p) (1 × 108 TU/ml) was slowly injected into mice via the pancreatic duct (100 μl) after feeding for 24 weeks, as described previously [20]. Further measurements were performed at 4 weeks post-lentiviral infection. See ESM Methods. Experimenters were blind to group assignment and outcome assessment.

Serum NEFA profile and glucose and lipid measurement

Blood samples were collected for further detection. See ESM Methods.

miRNA microarray analysis

Oebiotech (Shanghai, China) performed the miRNA microarray work, processing 12 samples from mouse islets (n = 4 per group). See ESM Methods.

Co-staining using TUNEL assay and insulin-labelled islets

Islet injury was detected with the In Situ Cell Death Detection Kit (TUNEL Fluorescence Kit, Roche, Indianapolis, IN, USA). Islets were labelled with anti-insulin antibody (Cell Signaling Technology, Minneapolis, MN, USA), and viewed by confocal microscopy. See ESM Methods.

Pancreatic insulin content

The pancreas was extracted using the acid ethanol method as described previously [21], and the insulin level was detected.

Intravenous glucose tolerance tests

IVGTTs were performed on overnight-fasted mice. For the measurement of insulin and glucose levels, blood samples were collected at 0, 1, 5, 10, 20, 30 and 60 min after glucose administration (0.75 g/kg) to the tail vein.

Beta cell mass and histochemical analysis

The pancreatic tissues were fixed, embedded in paraffin and stained with anti-insulin and anti-glucagon antibodies. See ESM Methods.

Insulin granules analysis

Electron microscopy was employed to analyse the content of insulin granules in fixed pancreatic tissues as described previously [22].

Cell culture

Rat insulinoma cell line INS-1 cells were cultured and treated with 600 μmol/l stearic or other fatty acids for 24 h. Mouse pancreatic islets were isolated as described previously [23]. See ESM Methods. Experimenters were blind to group assignment and outcome assessment.

Cell viability measurements

Cell viability was determined by assessment of lactate dehydrogenase (LDH) release, propidium iodide (PI) staining, 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay and Hoechst staining. See ESM Methods.

Transfection procedures

INS-1 cells were transfected with oligonucleotides or recombinant plasmid using Lipofectamine 2000 (Invitrogen), as described previously [24], and used in detection assays 48 h after transfection.

Luciferase activity assay

The luciferase activity was detected using a luciferase activity assay. See ESM Methods.

Quantitative PCR

The mRNA and miRNA levels were determined by quantitative PCR (qPCR). See ESM Methods. The primer sequences are shown in ESM Table 2.

Western blot

The western blot procedure has been described previously [25]. See ESM Methods.

Insulin measurements

Insulin levels in mouse serum and cell culture media were determined by mouse/rat insulin ELISA kit (Linco Research, St Charles, MO, USA). To assess glucose-induced insulin secretion (GSIS), cells were incubated in secretion buffer (see ESM Methods) for an additional 60 min with 2.8 or 20 mmol/l glucose.

Statistics

Values are expressed as mean ± SD. Multiple groups were analysed with one-way ANOVA followed by a Student–Newman–Keuls test. Two-group-only comparisons were carried out by t test. A two-sided p value < 0.05 was considered statistically significant. Repeated-measures ANOVA was used to analyse the glucose and insulin levels during IVGTT.

Results

Stearic acid induces more severe lipotoxicity than palmitic acid

As shown in ESM Fig. 1a, b, only stearic and palmitic acids had an obviously lipotoxic effect on tested cells. The dose–response curves for palmitic and stearic acids are shown in ESM Fig. 1c. A mouse model with different stearic/palmitic acid ratios was subsequently established to mimic and investigate the lipotoxicity of increased proportions of stearic acid in hyperlipidaemia. The model was successfully established, as evidenced by significant elevation of circulating stearic and palmitic acid levels in the HSD and HPD groups, respectively, compared with controls (ESM Table 3). Importantly, the palmitic acid:stearic acid ratio was lower than controls in the HSD group (1.7:1 vs 2.7:1, respectively) but higher in the HPD group (6.2:1) (ESM Fig. 2). Body weight, total cholesterol (TC), triacylglycerol (TG), and LDL-cholesterol (LDL-C) were markedly higher in both HSD and HPD mice, whereas HDL-cholesterol (HDL-C) was significantly lower than in control mice (ESM Table 4). TUNEL results showed that pancreases from HSD mice contained more TUNEL-positive islets than pancreases from HPD mice, and beta cell mass was lower in the HSD group (Fig. 1a). Subsequently, the levels of cleaved PARP-1 and cleaved caspase-3 was increased in pancreatic islets (Fig. 1b). Further, the impaired glucose tolerance and second-phase insulin secretion in response to glucose were significantly enhanced in the HSD group compared with the HPD group (Fig. 1c, d). Also, immunohistochemical analysis of pancreatic tissue showed that the islets of HSD mice comprised more glucagon-positive cells than both normal mice and the HPD group (Fig. 1e). These data suggest that HSD feeding is more detrimental to islet cells than HPD feeding. We next incubated INS-1 cells in culture media with different ratios of palmitic/stearic acid for 24 h and measured cytotoxicity with Hoechst 33342 staining (Fig. 1f) and MTT assay (Fig. 1g). The results showed that lipotoxicity was enhanced in the presence of a higher proportion of stearic acid, and levels of cleaved PARP-1 and cleaved caspase-3 proteins were elevated accordingly (Fig. 1h). Additionally, GSIS in stearic-acid-treated INS-1 supernatant fractions was dramatically lower than in palmitic-acid-treated cells (Fig. 1i).
Fig. 1

Comparison of the lipotoxic effect of stearic acid (SA) and palmitic acid (PA) on islets and INS-1 cells. TUNEL staining (scale bar, 10 μm) (a), western blot analysis of cleaved PARP-1 and cleaved caspase 3 (b), blood glucose (c) and insulin (d) levels during IVGTT and immunohistochemical analysis of pancreas sections (scale bar, 100 μm) (e), from control, HSD and HPD mice; n = 6 per group. In (a) islets are red and TUNEL-positive regions are green. In (c, d) circles, control; squares, HSD; inverted triangles, HPD. *p < 0.05 and **p < 0.01 vs control; p < 0.05 and †† p < 0.01 vs HSD. Lipotoxic effect of different PA:SA molar ratios (total concentration, 600 μmol/l) on INS-1 cells measured by Hoechst staining (scale bar, 10 μm) (f), MTT assay (g), immunoblots of cleaved PARP-1/cleaved caspase 3 (h) and GSIS (i). *p < 0.05 vs control; p < 0.05 vs PA. The test was performed five times. Ctrl, control

Stearic acid increases miR-34a-5p levels in both mouse islets and INS-1 cells

In HSD islets, 40 miRNAs were differentially expressed (ten up- and 30 downregulated ≥2.0-fold change and p < 0.05), whereas in HPD islets, 77 miRNAs were highly dysregulated (31 up- and 46 downregulated ≥2.0-fold change and p < 0.05), compared with normal mice (ESM Table 5). A heat map of HSD and HPD islet miRNA expression ratios (log2 scale) is shown in ESM Fig. 3. Furthermore, we screened out six upregulated and 13 downregulated miRNAs that responded to an HSD, compared with both control and HPD groups (≥2.0 fold change and p < 0.05, Fig. 2a). Among these, miR-34a-5p expression increased the most, 6.35-fold in HSD and 1.57-fold in HPD mice, respectively.
Fig. 2

Differential expression of miRNAs in islets and INS-1 cells. (a) Heat maps and hierarchical clustering of expression ratios (log–log scale) of miRNAs in HSD mouse islets compared with both HPD and control mice. High relative expression is shown in red and low relative expression in green. n = 4 per group. (b, c) qPCR verifies upregulation of miR-34a-5p in mice (b) and INS-1 cells (c). *p < 0.05 and **p < 0.01 vs controls; p < 0.05 vs HSD or palmitic acid; n = 6 per group; each in vitro test was performed five times. Ctrl, control; PA, palmitic acid; SA, stearic acid

Quantitative PCR verified that miR-34a-5p levels increased by 191% in HSD and 97% in HPD islets, respectively, compared with normal islets (Fig. 2b). In INS-1 cells exposed to different ratios of palmitic/stearic acids, miR-34a-5p expression was markedly upregulated compared with controls in cells exposed to a higher proportion of stearic acid, (Fig. 2c).

miR-34a-5p contributes to stearic-acid-induced lipotoxicity in islets and INS-1 cells

Transfection of AMO-34a-5p into stearic-acid-treated INS-1 cells efficiently reduced intracellular miR-34a-5p levels (ESM Fig. 4), inhibited stearic-acid-induced cell death (Fig. 3a, b), and reversed stearic-acid-increased cleaved PARP-1 and cleaved caspase-3 levels (Fig. 3c). Accordingly, stearic-acid-decreased GSIS was apparently restored after miR-34a-5p inhibition (Fig. 3d). However, transfecting only miR-34a-5p into INS-1 cells also induced cell death and a reduction in GSIS, which were reversed by AMO-34a-5p (ESM Fig. 5a–d). In vivo, the lenti-AMO-34a-5p was successfully delivered into the pancreas as evidenced by the strong green fluorescence (ESM Fig. 6a), with endogenous miR-34a-5p expression almost completely silenced (up to 95%) in islets (ESM Fig. 6b). HSD-induced islet damage in mice was robustly alleviated by lenti-AMO-34a-5p injection, consistent with the decreased number of TUNEL-positive islets and increased beta cell mass (Fig. 3e), decreased levels of cleaved PARP-1 and cleaved caspase-3 proteins (Fig. 3f) and improved glucose tolerance (Fig. 3g). Importantly, the first-phase insulin release was significantly enhanced and second-phase insulin secretion was decreased after lenti-AMO-34a-5p injection (Fig. 3h), which indicates that inhibition of miR-34a-5p could enhance the capacity to increase GSIS. Also, the number of alpha cells in the HSD + lenti-AMO-34a-5p group was significantly reduced and the normal cell distribution pattern was restored (Fig. 3i). Additionally, stearic-acid-mediated reductions in pancreatic insulin content (ESM Fig. 6c) and insulin granules (ESM Fig. 6d) were apparently reversed. The body weight and serum lipid level were not altered (ESM Table 6).
Fig. 3

Inhibition of miR-34a-5p improves stearic-acid-induced lipotoxicity in islets and INS-1 cells. Hoechst staining (scale bar, 10 μm) (a), MTT assay (b), immunoblotting of cleaved PARP-1/cleaved caspase 3 (c) and GSIS (d) showing the effect of AMO-34a-5p on apoptosis in stearic acid-treated INS-1 cells. * p < 0.05 vs control; p < 0.05 vs SA; each test was performed five times. TUNEL assay (e), western blot for cleaved PARP-1 cleaved caspase 3 (f), blood glucose (g) and insulin (h) level during IVGTT, and immunohistochemical analysis of pancreatic sections (scale bar, 100 μm) (i), showing the effect of lenti-AMO-34a-5p on HSD islets. In (e) islets are red and TUNEL-positive regions are green (scale bar, 10 μm). Circles, control + lentiviral vector expressing scrambled AMO oligonucleotide (lenti-Scr); squares HSD + lenti-Scr; inverted triangles, HSD + lenti-AMO-34a-5p. *p < 0.05 and **p < 0.01 vs control + lenti-Scr; p < 0.05 and †† p < 0.01 vs HSD + lenti-Scr. n = 6 per group. AMO, anti-miRNA oligonucleotide; Ctrl, control; MT, mutant; PA, palmitic acid; SA, stearic acid

miR-34a-5p specifically represses BCL-2 and BCL-W expression

Expression of B cell CLL/lymphoma 2 (BCL-2) and BCL-2-like 2 (BCL-W) was reduced in both HSD islets and stearic-acid-treated INS-1 cells (Fig. 4a, b). AMO-34a-5p treatment, either in vitro or in vivo, markedly reversed stearic-acid-mediated downregulation of BCL-2 and BCL-W proteins, (Fig. 4c, d). In INS-1 cells overexpressing miR-34a-5p, levels of BCL-2 as well as BCL-W were decreased, but were efficiently rescued by addition of AMO-34a-5p (Fig. 4e). Furthermore, luciferase assay verified that overexpression of miR-34a-5p inhibited luciferase activity in human embryonic kidney 293 (HEK293) cells transfected with plasmid carrying the 3′ UTR of either the Bcl2 or the Bcl2l2 gene (Fig. 4f).
Fig. 4

Repression of Bcl2 and Bcl2l2 genes by miR-34a-5p. Downregulation of BCL-2/BCL-W in HSD islets (a) and stearic acid-treated INS-1 cells (b). Expression of BCL-2/BCL-W by AMO-34a-5p in SA-treated INS-1 cells (c) and HSD islets (d). (e) Effect of miR-34a-5p on BCL-2/BCL-W expression. (f) Effect of miR-34a-5p on the 3′ UTR of Bcl2 and Bcl2l2 determined by luciferase activity assay. *p < 0.05 vs control, p < 0.05 for the indicated comparison. n = 6 mice per group; each in vitro test was performed five times. AMO, anti-miRNA oligonucleotide; Ctrl, control; MT, mutant; PA, palmitic acid; pmiR-RB, pmiR-RB REPORT; SA, stearic acid

p53 is involved in stearic acid-induced elevation of miR-34a-5p

The amount of p53 protein increased in HSD islets and stearic-acid-treated INS-1 cells (ESM Fig. 7a). Stearic-acid-induced lipotoxicity was abrogated after silencing p53 (also known as Trp53), accompanied by a 75% reduction in stearic-acid-increased miR-34a-5p (Fig. 5a–c). Meanwhile, stearic-acid-elicited upregulation of cleaved PARP-1 and cleaved caspase-3, as well as the downregulation of BCL-2 and BCL-W protein expression, was rescued by p53 knockdown (Fig. 5d).
Fig. 5

Involvement of p53 in stearic-acid-induced stimulation of miR-34a-5p in INS-1 cells. Effect of p53 siRNA on miR-34a-5p levels (a), cell viability (b), apoptosis (scale bar, 10 μm) (c), and cleaved PARP-1/caspase 3/BCL-2/BCL-W protein expression (d) with/without stearic acid. *p < 0.05 vs control; p < 0.05 vs SA + siRNA-negative control; the test was performed five times. Ctrl, control; NC, negative control; SA, stearic acid

PERK contributes to stearic-acid-induced upregulation of miR-34a-5p and lipotoxicity

Our in vitro results showed that the transmembrane sensors of ER stress, including inositol-requiring-enzyme 1 (IRE1), activating transcription factor 6 (ATF6) and PERK, are strongly upregulated by stearic acid treatment. Similarly, ER stress marker proteins, such as CHOP and glucose-regulated protein 78 kDa (GRP78), were also enhanced (ESM Fig. 7b). Genetically silencing Perk (also known as Eif2ak3) by small interfering RNA (siRNA) in INS-1 cells significantly blocked the stearic-acid-induced increase in p53 expression (Fig. 6a), miR-34a-5p level (Fig. 6b) and lipotoxicity (Fig. 6c, d). Accordingly, stearic-acid-increased expression of cleaved PARP-1 and cleaved caspase 3, as well as -suppressed BCL-2 and BCL-W, returned to basal levels after inhibition of Perk expression (Fig. 6e). However, gene silencing of neither Ire1 nor Atf6 inhibited the stearic-acid-induced changes detected above (ESM Fig. 8). Further, the phosphorylated level of eukaryotic translation initiation factor (eIF)2α was significantly enhanced after stearic acid exposure (ESM Fig. 9). The inhibitory efficiency of siRNAs targeting p53, Ire1, Atf6 and Perk are shown in ESM Fig. 10.
Fig. 6

Involvement of PERK in stearic acid-induced stimulation of miR-34a-5p via p53 in INS-1 cells. Effect of Perk siRNA on p53 protein expression (a), miR-34a-5p levels (b), cell survival (c), apoptosis (scale bar, 10 μm) (d), and cleaved PARP-1/cleaved caspase 3/BCL-2/BCL-W protein expression (e) with/without SA. *p < 0.05 vs control; p < 0.05 vs SA + siRNA-negative control; the test was performed five times. Ctrl, control; NC, negative control; SA, stearic acid

Discussion

In this study, we provide evidence that, relative to other NEFA, stearic acid is the major contributor to lipotoxicity in beta cells, implying that an increased concentration of serum stearic acid plays a fundamental role in the development of beta cell dysfunction and type 2 diabetes. Our mechanistic studies revealed that miR-34a-5p upregulation modulates stearic-acid-induced lipotoxicity by inhibiting the production of BCL-2 and BCL-W proteins. Additional studies have also demonstrated that the ER-stress-related sensor PERK contributes to stearic-acid-induced upregulation of miR-34a-5p in a p53-dependent signalling pathway.

Although alterations in the NEFA profiles of people with hyperlipidaemia have been widely investigated, the NEFA that is most directly associated with beta cell lipotoxicity remains unclear. Therefore, we first selected NEFA with statistically discrepant levels between healthy and hyperlipidaemic individuals to test their cytotoxicity to pancreatic beta cells. We observed that only stearic and palmitic acids significantly lowered cell viability. Incubating cells in medium containing different ratios of palmitic acid:stearic acid dramatically enhanced cytotoxicity, but insulin secretion was reduced as the proportion of stearic acid was increased. The concentrations of palmitic and stearic acids used in this study were selected to avoid excessive cell death based on previous reports and our previous experiments [7, 26, 27], though this does not happen in human or animal pancreatic beta cells in vivo [26, 27]. The concentrations of palmitic and stearic acids employed in cultured cells were, in fact, lower than in patients with hyperlipidaemia, but induced more severe damage than in the in vivo system, which could be explained by the existence of protective factors (i.e. unsaturated fatty acids [4, 5, 6]). Additionally, we observed that eicosapentaenoic acid (EPA; C20:5), a potential protective factor, was reduced in both HSD and HPD mice, and this might also contribute to high-fat-diet-induced lipotoxicity. Unlike the in vitro system, it is unrealistic to establish animal models with only stearic- or palmitic-acid-constructed lipid profiles in blood. However, a well-accepted approach to compare different biological function among the different types of NEFA was achieved by regulating the blood NEFA ratio using various oils as a fat source in the high-fat diet [28, 29]. In this study, models of hyperlipidaemia with high circulating levels of either stearic or palmitic acid were established using lard or palm oil as a fat source, consistent with previous studies [28, 29, 30]. After 24 weeks of feeding, the fasting serum levels of stearic and palmitic acids increased in HSD and HPD mice, respectively. The palmitic acid:stearic acid ratio was 1.7:1 and 6.2:1 in HSD and HPD mice, respectively. Subsequently, the HSD mice showed significant impairment of glucose tolerance and GSIS compared with HPD mice, with an increased number of apoptotic beta cells leading to a decrease in beta cell mass. Our results clearly show that, in vivo, HSD induces more damage in islets than HPD, consistent with the in vitro results. No difference was observed in the total SFA content between the HSD and HPD groups, excluding the possibility that the different extent of lipotoxicity was caused by something other than differences in lipid concentrations. Additionally, these results are also consistent with our previous findings [7, 31], indicating that stearic acid appears to be a more important risk factor for type 2 diabetes than other NEFA. Therefore, great attention should be paid to elevated serum stearic acid, as it appears to have a greater negative impact on beta cell function.

The mechanistic pathways responsible for HSD-induced lipotoxicity in pancreatic beta cells are not fully understood. Recent evidence has provided new clues that miRNAs are involved in the regulation of beta cell failure and type 2 diabetes [32, 33, 34]. In our study, we selected 19 miRNAs that are differentially expressed in islets of HSD mice relative to HPD and normal mice, based on gene-chip microarray analysis. Among these miRNAs, miR-34a-5p displayed the largest fold increase, which was in line with previous observations that a high level of miR-34a-5p was present in the islets of diabetic db/db mice and pancreatic islets exposed to palmitic acid [34]. To demonstrate the potential role of miR-34a-5p in HSD-mediated lipotoxicity in beta cells, endogenous miR-34a-5p was abrogated by AMO-34a-5p in both mice and INS-1 cells. Lenti-AMO-34a-5p injection ameliorated HSD-induced islet apoptosis in vivo. Accordingly, impaired glucose tolerance and GSIS in HSD mice were largely restored. The decrease in beta cell mass seen in HSD mice was also reversed. Insulin secretion and beta cell mass are two important factors for regulating glucose homeostasis through well-balanced beta cell compensation in the early stage of type 2 diabetes, but they gradually worsen [35, 36]. Our results indicate that miR-34a-5p inhibition in HSD islets could probably improve the beta cell dysfunction and further slow the progression of type 2 diabetes. In vitro, AMO-34a-5p relieved the cytotoxic effect of stearic acid and reversed the reduction in insulin secretion. Conversely, overexpression of miR-34a-5p significantly enhanced cytotoxicity and reduced GSIS. These results strongly suggest that miR-34a-5p plays a crucial role in elevating lipotoxicity induced by serum stearic acid. However, the stearic-acid-mediated decrease in GSIS was not completely reversed by miR-34a-5p inhibition, which implies that a non-miR-34a-5p-mediated mechanism operated in GSIS reduction. We also observed that miR-34a-5p levels were higher in HSD islets and stearic-acid-treated INS-1 cells than in HPD islets and the palmitic acid group, respectively, which suggests that the greater adverse effect of stearic over palmitic acid on beta cells, both in vivo and in vitro, is probably attributable to differential regulation of miR-34a-5p.

Previous studies have indicated that miR-34a-5p is closely associated with apoptosis through the BCL-2 family in cancer cells, tubular cells and cardiomyocytes [37, 38, 39]. The BCL-2 family includes both anti-apoptosis members (BCL-2, BCL-2-like 1 [BCL-XL] and BCL-W) and pro-apoptosis members (BCL-2-associated X protein [BAX], BCL-2-antagonist/killer [BAK] and BCL-2-associated agonist of cell death [BAD]) [40, 41]. In our study, we confirmed that BCL-2 and BCL-W are direct targets of miR-34a-5p using luciferase activity assays. However, how stearic acid regulates miR-34a-5p levels is still unclear. Accumulating evidence supports p53 as a classic transcription factor regulating miR-34a-5p. To further investigate the involvement of p53 in miR-34a-5p upregulation after long-term incubation of INS-1 cells with stearic acid, we silenced p53 and then investigated whether miR-34a-5p levels were reversed, with an associated reduction in lipotoxicity, which would suggest that the mechanism underlying HSD-induced stimulation of miR-34a-5p uses a p53-dependent pathway.

Enhanced ER stress, associated with beta cell lipotoxicity, transduces apoptotic signals in the early stage of type 2 diabetes [42]. Three major signalling pathways separately initiated by ER transmembrane sensor proteins, including IRE1, PERK and ATF6, are involved in ER stress [43]. We subsequently knocked down Ire1, Perk and Atf6 with siRNAs in stearic-acid-treated INS-1 cells, and found that inhibition of Ire1 and Atf6 failed to inhibit stearic-acid-induced stimulation of miR-34a-5p. However, transfection of siRNA for Perk attenuated lipotoxicity and miR-34a-5p levels on stearic acid treatment. These findings demonstrate that miR-34a-5p might be promoted by PERK in conditions of ER stress. We also discovered that PERK exhibited an inhibitory effect on p53 protein expression, suggesting that a PERK–p53–miR-34a-5p axis is mechanistically involved in stearic-acid-induced lipotoxicity in beta cells.

Additionally, the inflammatory response was the common reaction during prolonged exposure to NEFA, which in turn results in the aggravation of lipotoxicity. Chronic exposure to inflammatory conditions leads to beta cell dysfunction and apoptosis [32, 44, 45]. A recent investigation has revealed that the level of miR-34a increased concomitantly in cytokine-treated MIN6 cells and human pancreatic islets, and contributed to beta cell dysfunction [32]. Therefore, we proposed that the HSD-induced increase in miR-34a-5p and further pancreatic injury probably represented an important inflammatory response pathway. This needs to be clarified in future studies.

In conclusion, we provide evidence that elevated levels of circulating stearic acid induce severe lipotoxicity in pancreatic beta cells. It appears that upregulation of miR-34a-5p and the associated inhibition of BCL-2/BCL-W play a critical role in mediating stearic acid cytotoxicity. Our results also suggest a regulatory role for PERK in miR-34a-5p expression and that p53 is a mediator of PERK-induced miR-34a-5p upregulation. Collectively, these findings allow us to propose a novel signalling pathway linking stearic acid to lipotoxicity in beta cells: stearic acid–PERK–p53-miR-34a-5p–BCL-2/BCL-W. These findings provide a novel insight into stearic-acid-induced lipotoxicity and progression of type 2 diabetes, whereby lowering miR-34a-5p might be an effective strategy for improving lipotoxicity in beta cells.

Notes

Acknowledgements

We thank B. X. Wu (Department of Nutrition and Food Hygiene, Public Health College, Harbin Medical University) for helping with serum glucose and lipid measurement and Q. N. Qu and Y. Y. Liu (Department of Nutrition and Food Hygiene, Public Health College, Harbin Medical University) for help with animal feeding.

Funding

This work was supported by the State Key Program of National Natural Science of China (grant number 81130049), and the National Natural Science Foundation of China (grant numbers 81202187, 81202188 and 81202191).

Duality of interest

The authors declare that there is no duality of interest associated with this manuscript.

Contribution statement

CS, LN and SLi conceived the experiments, analysed and interpreted the data and reviewed and edited the manuscript. HL and SLi were responsible for designing and performing the study, acquisition and analysis of data and writing the draft of the manuscript. HL, LH, SLin, LL, YC, HC, TZ, XC and LN performed the study, collected data and interpreted and drafted the manuscript. All authors approved the final version of the manuscript. CS is the guarantor of this work.

Supplementary material

125_2016_3900_MOESM1_ESM.pdf (236 kb)
ESM Methods (PDF 235 kb)
125_2016_3900_MOESM2_ESM.pdf (216 kb)
ESM Fig. 1 (PDF 215 kb)
125_2016_3900_MOESM3_ESM.pdf (70 kb)
ESM Fig. 2 (PDF 69 kb)
125_2016_3900_MOESM4_ESM.pdf (168 kb)
ESM Fig. 3 (PDF 167 kb)
125_2016_3900_MOESM5_ESM.pdf (144 kb)
ESM Fig. 4 (PDF 144 kb)
125_2016_3900_MOESM6_ESM.pdf (240 kb)
ESM Fig. 5 (PDF 240 kb)
125_2016_3900_MOESM7_ESM.pdf (237 kb)
ESM Fig. 6 (PDF 237 kb)
125_2016_3900_MOESM8_ESM.pdf (200 kb)
ESM Fig. 7 (PDF 199 kb)
125_2016_3900_MOESM9_ESM.pdf (334 kb)
ESM Fig. 8 (PDF 334 kb)
125_2016_3900_MOESM10_ESM.pdf (38 kb)
ESM Fig. 9 (PDF 38 kb)
125_2016_3900_MOESM11_ESM.pdf (21 kb)
ESM Fig. 10 (PDF 20 kb)
125_2016_3900_MOESM12_ESM.pdf (18 kb)
ESM Table 1 (PDF 17 kb)
125_2016_3900_MOESM13_ESM.pdf (73 kb)
ESM Table 2 (PDF 73 kb)
125_2016_3900_MOESM14_ESM.pdf (141 kb)
ESM Table 3 (PDF 141 kb)
125_2016_3900_MOESM15_ESM.pdf (10 kb)
ESM Table 4 (PDF 9 kb)
125_2016_3900_MOESM16_ESM.pdf (72 kb)
ESM Table 5 (PDF 72 kb)
125_2016_3900_MOESM17_ESM.pdf (10 kb)
ESM Table 6 (PDF 9 kb)

References

  1. 1.
    Elsner M, Gehrmann W, Lenzen S (2011) Peroxisome-generated hydrogen peroxide as important mediator of lipotoxicity in insulin-producing cells. Diabetes 60:200–208CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Giacca A, Xiao C, Oprescu AI, Carpentier AC, Lewis GF (2011) Lipid-induced pancreatic β-cell dysfunction: focus on in vivo studies. Am J Physiol Endocrinol Metab 300:E255–E262CrossRefPubMedGoogle Scholar
  3. 3.
    Hodson DJ, Mitchell RK, Bellomo EA et al (2013) Lipotoxicity disrupts incretin-regulated human β cell connectivity. J Clin Invest 123:4182–4194CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Listenberger LL, Han X, Lewis SE et al (2003) Triglyceride accumulation protects against fatty acid-induced lipotoxicity. Proc Natl Acad Sci U S A 100:3077–3082CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Zhang Y, Dong L, Yang X, Shi H, Zhang L (2011) α-Linolenic acid prevents endoplasmic reticulum stress-mediated apoptosis of stearic acid lipotoxicity on primary rat hepatocytes. Lipids Health Dis 10:81CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Cheon HG, Cho YS (2014) Protection of palmitic acid-mediated lipotoxicity by arachidonic acid via channeling of palmitic acid into triglycerides in C2C12. J Biomed Sci 21:13CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Chu X, Liu L, Na L et al (2013) Sterol regulatory element-binding protein-1c mediates increase of postprandial stearic acid, a potential target for improving insulin resistance, in hyperlipidemia. Diabetes 62:561–571CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Galbo T, Perry RJ, Jurczak MJ et al (2013) Saturated and unsaturated fat induce hepatic insulin resistance independently of TLR-4 signaling and ceramide synthesis in vivo. Proc Natl Acad Sci U S A 110:12780–12785CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Hernandez TL, Sutherland JP, Wolfe P et al (2010) Lack of suppression of circulating free fatty acids and hypercholesterolemia during weight loss on a high-fat, low-carbohydrate diet. Am J Clin Nutr 91:578–585CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Hirabara SM, Curi R, Maechler P (2010) Saturated fatty acid-induced insulin resistance is associated with mitochondrial dysfunction in skeletal muscle cells. J Cell Physiol 222:187–194CrossRefPubMedGoogle Scholar
  11. 11.
    Sawada K, Kawabata K, Yamashita T, Kawasaki K, Yamamoto N, Ashida H (2012) Ameliorative effects of polyunsaturated fatty acids against palmitic acid-induced insulin resistance in L6 skeletal muscle cells. Lipids Health Dis 11:36CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Zhang K (2015) Endoplasmic reticulum stress response and transcriptional reprogramming. Front Genet 5:460CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Gan LT, Van Rooyen DM, Koina ME, McCuskey RS, Teoh NC, Farrell GC (2014) Hepatocyte free cholesterol lipotoxicity results from JNK1-mediated mitochondrial injury and is HMGB1 and TLR4-dependent. J Hepatol 61:1376–1384CrossRefPubMedGoogle Scholar
  14. 14.
    Cazanave SC, Elmi NA, Akazawa Y, Bronk SF, Mott JL, Gores GJ (2010) CHOP and AP-1 cooperatively mediate PUMA expression during lipoapoptosis. Am J Physiol Gastrointest Liver Physiol 299:G236–G243CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Kakisaka K, Cazanave SC, Fingas CD et al (2012) Mechanisms of lysophosphatidylcholine-induced hepatocyte lipoapoptosis. Am J Physiol Gastrointest Liver Physiol 302:G77–G84CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Egnatchik RA, Leamy AK, Jacobson DA, Shiota M, Young JD (2014) ER calcium release promotes mitochondrial dysfunction and hepatic cell lipotoxicity in response to palmitate overload. Mol Metab 3:544–553CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Miyamoto Y, Mauer AS, Kumar S, Mott JL, Malhi H (2014) Mmu-miR-615-3p regulates lipoapoptosis by inhibiting C/EBP homologous protein. PLoS One 9, e109637CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Kuwabara Y, Horie T, Baba O et al (2015) MicroRNA-451 exacerbates lipotoxicity in cardiac myocytes and high-fat diet-induced cardiac hypertrophy in mice through suppression of the LKB1/AMPK pathway. Circ Res 116:279–288CrossRefPubMedGoogle Scholar
  19. 19.
    Goldstein JL, Basu SK, Brown MS (1983) Receptor-mediated endocytosis of low-density lipoprotein in cultured cells. Methods Enzymol 98:241–260CrossRefPubMedGoogle Scholar
  20. 20.
    Doiron B, Hu W, Norton L, DeFronzo RA (2012) Lentivirus shRNA Grb10 targeting the pancreas induces apoptosis and improved glucose tolerance due to decreased plasma glucagon levels. Diabetologia 55:719–728CrossRefPubMedGoogle Scholar
  21. 21.
    Portha B, Picon L, Rosselin G (1979) Chemical diabetes in the adult rat as the spontaneous evolution of neonatal diabetes. Diabetologia 17:371–377CrossRefPubMedGoogle Scholar
  22. 22.
    Wang H, Ishizaki R, Kobayashi E, Fujiwara T, Akagawa K, Izumi T (2011) Loss of granuphilin and loss of syntaxin-1A cause differential effects on insulin granule docking and fusion. J Biol Chem 286:32244–32250CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Sutton R, Peters M, McShane P, Gray DW, Morris PJ (1986) Isolation of rat pancreatic islets by ductal injection of collagenase. Transplantation 42:689–691CrossRefPubMedGoogle Scholar
  24. 24.
    Yang B, Lin H, Xiao J et al (2007) The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2. Nat Med 13:486–491CrossRefPubMedGoogle Scholar
  25. 25.
    Lu N, Li Y, Qin H, Zhang YL, Sun CH (2008) Gossypin up-regulates LDL receptor through activation of ERK pathway: a signaling mechanism for the hypocholesterolemic effect. J Agric Food Chem 56:11526–11532CrossRefPubMedGoogle Scholar
  26. 26.
    Thörn K, Bergsten P (2010) Fatty acid-induced oxidation and triglyceride formation is higher in insulin-producing MIN6 cells exposed to oleate compared to palmitate. J Cell Biochem 111:497–507CrossRefPubMedGoogle Scholar
  27. 27.
    Litwak SA, Wali JA, Pappas EG et al (2015) Lipotoxic stress induces pancreatic β-cell apoptosis through modulation of Bcl-2 proteins by the ubiquitin-proteasome system. J Diabetes Res 2015:280615CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    van den Berg SA, Guigas B, Bijland S et al (2010) High levels of dietary stearate promote adiposity and deteriorate hepatic insulin sensitivity. Nutr Metab (Lond) 7:24CrossRefGoogle Scholar
  29. 29.
    Tholstrup T, Hjerpsted J, Raff M (2011) Palm olein increases plasma cholesterol moderately compared with olive oil in healthy individuals. Am J Clin Nutr 94:1426–1432CrossRefPubMedGoogle Scholar
  30. 30.
    Dobbins RL, Szczepaniak LS, Myhill J et al (2002) The composition of dietary fat directly influences glucose-stimulated insulin secretion in rats. Diabetes 51:1825–1833CrossRefPubMedGoogle Scholar
  31. 31.
    Liu L, Li Y, Guan C et al (2010) Free fatty acid metabolic profile and biomarkers of isolated post-challenge diabetes and type 2 diabetes mellitus based on GC-MS and multivariate statistical analysis. J Chromatogr B Analyt Technol Biomed Life Sci 878:2817–2825CrossRefPubMedGoogle Scholar
  32. 32.
    Roggli E, Britan A, Gattesco S et al (2010) Involvement of microRNAs in the cytotoxic effects exerted by proinflammatory cytokines on pancreatic beta-cells. Diabetes 59:978–986CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Belgardt BF, Ahmed K, Spranger M et al (2015) The microRNA-200 family regulates pancreatic beta cell survival in type 2 diabetes. Nat Med 21:619–627CrossRefPubMedGoogle Scholar
  34. 34.
    Lovis P, Roggli E, Laybutt DR et al (2008) Alterations in microRNA expression contribute to fatty acid-induced pancreatic beta-cell dysfunction. Diabetes 57:2728–2736CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Thorens B (2013) The required beta cell research for improving treatment of type 2 diabetes. J Intern Med 274(3):203–214CrossRefPubMedGoogle Scholar
  36. 36.
    Plaisance V, Waeber G, Regazzi R, Abderrahmani A (2014) Role of microRNAs in islet beta-cell compensation and failure during diabetes. J Diabetes Res 2014:618652PubMedPubMedCentralGoogle Scholar
  37. 37.
    Ji X, Wang Z, Geamanu A, Goja A, Sarkar FH, Gupta SV (2012) Delta-tocotrienol suppresses Notch-1 pathway by upregulating miR-34a in nonsmall cell lung cancer cells. Int J Cancer 131:2668–2677CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Zhou Y, Xiong M, Niu J et al (2014) Secreted fibroblast-derived miR-34a induces tubular cell apoptosis in fibrotic kidney. J Cell Sci 127:4494–4506CrossRefPubMedGoogle Scholar
  39. 39.
    Peng X, Shao J, Shen Y et al (2013) FAT10 protects cardiac myocytes against apoptosis. J Mol Cell Cardiol 59:1–10CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Lin CJ, Gong HY, Tseng HC, Wang WL, Wu JL (2008) miR-122 targets an anti-apoptotic gene, Bcl-w, in human hepatocellular carcinoma cell lines. Biochem Biophys Res Commun 375:315–320CrossRefPubMedGoogle Scholar
  41. 41.
    Petros AM, Olejniczak ET, Fesik SW (2004) Structural biology of the Bcl-2 family of proteins. Biochim Biophys Acta 1644:83–94CrossRefPubMedGoogle Scholar
  42. 42.
    Wali JA, Masters SL, Thomas HE (2013) Linking metabolic abnormalities to apoptotic pathways in beta cells in type 2 diabetes. Cells 2:266–283CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Gardner BM, Pincus D, Gotthardt K, Gallagher CM, Walter P (2013) Endoplasmic reticulum stress sensing in the unfolded protein response. Cold Spring Harb Perspect Biol 5:a013169CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Roggli E, Gattesco S, Caille D et al (2012) Changes in microRNA expression contribute to pancreatic β-cell dysfunction in prediabetic NOD mice. Diabetes 61:1742–1751CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Roggli E, Gattesco S, Pautz A, Regazzi R (2012) Involvement of the RNA-binding protein ARE/poly(U)-binding factor 1 (AUF1) in the cytotoxic effects of proinflammatory cytokines on pancreatic beta cells. Diabetologia 55:1699–1708CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • Huimin Lu
    • 1
  • Liuyi Hao
    • 1
  • Songtao Li
    • 1
  • Song Lin
    • 1
  • Lin Lv
    • 1
  • Yang Chen
    • 1
  • Hongli Cui
    • 1
  • Tianqi Zi
    • 1
  • Xia Chu
    • 1
  • Lixin Na
    • 1
    Email author
  • Changhao Sun
    • 1
    • 2
    Email author
  1. 1.Department of Nutrition and Food Hygiene, Public Health CollegeHarbin Medical UniversityHarbinPeople’s Republic of China
  2. 2.Research Institute of Food, Nutrition and Health, Sino-Russian Medical Research CenterHarbin Medical UniversityHarbinPeople’s Republic of China

Personalised recommendations